Time trends in the incidence and causes of blindness in Israel.
about
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive reviewDefining response to anti-VEGF therapies in neovascular AMD[Requirements for low vision magnification aids in age-related macular degeneration: Data from the Tübingen low vision clinic (comparison of 2007-2011 with 1999-2005)].Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment.The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration.Blindness and visual impairment in Germany: a slight fall in prevalencePrevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United KingdomProfile of conbercept in the treatment of neovascular age-related macular degeneration.Primary care physicians' role perception and self-reported performance in glaucoma care: a survey studyPre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders.The prevalence and causes of visual impairment and blindness among older adults in the city of Lodz, Poland.Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.Transformational change: nurses substituting for ophthalmologists for intravitreal injections - a quality-improvement report.Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review.A safety evaluation of ranibizumab in the treatment of age-related macular degeneration.Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future.Implementation studies of ranibizumab for neovascular age-related macular degeneration.Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration - a population- and register-based study from northern Sweden.Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death.The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care.Danish Rural Eye Study: Epidemiology of Adult Visual Impairment.[Design of the ORCA module in the OCEAN study : Evaluation of SD-OCT results in daily routine practice].Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK.Problems and perspectives of ophthalmic research in Germany: results from a national survey.The influence of visual impairment on pregnancy outcomes.Causes and Three-year Incidence of Irreversible Visual Impairment in Jing-An District, Shanghai, China from 2010-2015.Trends in the performance of quality indicators for diabetes care in the community and in diabetes-related health status: an Israeli ecological study.Rate of vision loss in neovascular age-related macular degeneration explored.Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using "Treat and Extend" Regimen.
P2860
Q26744068-AE1BE2E3-13CE-4BC4-AF81-9223DBC40082Q26996510-CEE3DCD9-6BC6-4A0E-90B0-E3E5645B86E3Q30964821-9B7D9928-265D-48FB-9A85-95C563D5B954Q33825687-ED34E66D-A317-4939-9237-8D5115D06814Q34158108-A0F03B88-5428-493E-A205-B687F0F1AE5AQ34352209-61E877C0-AFD6-42B3-800A-8160D24D3873Q35196853-C33F3042-DA0D-42E6-8AA6-701A26458CD5Q35541714-EF4CB1AB-1BB9-4F04-82EF-A9AEB4113790Q35865400-229E1001-E8BE-4B39-93C5-8BA6F8F5CE28Q35884984-95D439A9-E50B-4815-9970-489C83B2A313Q36152252-1F4239B2-F3AE-4682-8D93-77707480510AQ36762577-A058CAF7-818A-4CFB-8B80-1DDA7C777CA0Q37721864-828EA8B0-822D-412F-8F5C-FC1CB877B846Q38127625-ED1F366D-B8AD-4908-B4A9-073501BA2883Q38236770-005D42C6-47B1-419F-9A74-519405661C25Q38656865-4C2FA43A-B78D-4CB1-92F8-B9658B4E5892Q39316202-C7B28F92-AFA4-4715-9764-E6E7D2FC60E6Q39469868-831CF360-7CED-4109-891E-54195B4B2809Q39491363-02E6FF75-EACF-4006-ADEA-FFCAFE2ECD1CQ39598982-84D1E061-538F-4D39-95CB-DA080B145E8BQ40043259-8C90EBA6-B488-46AB-807A-6C3DCFF1A807Q40914780-0498D31C-55E9-4D22-B407-E55F20B72B80Q44558337-ACBA61B5-C7FC-4637-B54C-2FB24A7F3D17Q45421245-3E9EF85D-5A79-4563-8CC6-51509EA291FFQ46334532-D28C37FF-D5BB-4992-94BD-276F536F484CQ47407173-CB47A6E9-E18C-4715-BC44-A20C84848C4DQ47726839-6F0C9ADA-ABCF-4CF8-B49C-E15C93B000DAQ53666477-E3D892FB-9FA7-4F32-A51E-D6281E28B933Q55039184-47295D12-9999-44CA-83FB-A832279A8B30
P2860
Time trends in the incidence and causes of blindness in Israel.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Time trends in the incidence and causes of blindness in Israel.
@en
type
label
Time trends in the incidence and causes of blindness in Israel.
@en
prefLabel
Time trends in the incidence and causes of blindness in Israel.
@en
P2093
P1476
Time trends in the incidence and causes of blindness in Israel.
@en
P2093
Alon Skaat
Michael Belkin
Ofra Kalter-Leibovici
P304
214-221.e1
P356
10.1016/J.AJO.2011.08.035
P407
P577
2012-02-01T00:00:00Z